Author’s response to reviews

Title: Gigantol inhibits Wnt/β-catenin signaling and exhibits anticancer activity in breast cancer cells

Authors:

Desheng Lu (delu@suzu.edu.cn)
Shubin Yu (yusome@foxmail.com)
Zhongyuan Wang (wangzhongyuan@suzu.edu.cn)
Zijie Su (zijiesu@126.com)
Jiaxing Song (jxsong@suzu.edu.cn)
Liang Zhou (zts5711314@live.cn)
Qi Qi Sun (sunqi@suzu.edu.cn)
Shanshan Liu (lss@suzu.edu.cn)
Shiyue Li (627195917@qq.com)
Ying Li (liying826@suzu.edu.cn)
Meina Wang (wangmn@sinicaorchid.org)
Guo-Qiang Zhang (zhanggq@sinicaorchid.org)
Xue Zhang (syzxalice@163.com)
Zhong-Jian Liu (liuzj@sinicaorchid.org)

Version: 1 Date: 02 Jan 2018

Author’s response to reviews:

BCAM-D-17-01194

Shubin Yu et al: Gigantol inhibits Wnt/β-catenin signaling and exhibits anticancer activity in breast cancer cells
Dear Editor:

Thank you for forwarding the reviewers’ thoughtful comments. We have carefully addressed their concerns. The following paragraphs summarize the changes that have been made.

Reviewer 1 comments
Accept.
Response:
We appreciate the positive comment of the reviewer.

Reviewer 2 comments
The manuscript should be revised for linguistic, grammatical and style errors.
Response:
We thank the reviewer for pointing this out.
Based on the reviewer's comment, we have revised the original manuscript carefully, and linguistic, grammatical and style errors have been removed and corrected. In addition, the revised manuscript has been edited and proofread by a native English speaker. We believe that the manuscript has been greatly improved and hope it has reached your magazine’s standard.

Reviewer 3 comments
(1) Gigantol inhibits tumor growth in a breast cancer xenograft mouse model is highly recommended.
Response:
We are very grateful for the reviewer’s suggestion: gigantol inhibits tumor growth in a breast cancer xenograft mouse model is highly recommended.
To prove the anticancer activity of gigantol, relatively large amounts of gigantol are needed in a breast cancer mouse xenograft model. However, we could not get enough amounts of gigantol from the Chemical Companies to perform our experiment. A longer time will be needed for the
companies to produce enough amounts of gigantol. We will assess the anticancer activity of gigantol using MDA-MB-231 breast cancer xenografts and MMTV-Wnt1 transgenic mice as soon as we get enough amounts of gigantol.

(2) Where is the statistic analysis?
Response:
We thank the reviewer for pointing this out.
The results of statistic analysis were shown in Figure 1 and 5.
In Figure 1, * represent P<0.05 , and the following sentence was added in Figure Legend. “Statistical significance between groups is calculated by two-way ANOVA, *P < 0.05 compared to cells transfected with Wnt1, LRP6, or Wnt1 and LRP6, or incubated with Wnt3A-CM containing DMSO.”
Figure 5, * represent P<0.05, and the following sentence was added in Figure Legend. “Gigantol treatment significantly reduced the mRNA level of Axin2 and Survivin compared with DMSO treated control cells, * p < 0.05.”

(3) There are some English errors.
Response:
We thank the reviewer for pointing this out.
The English errors have been removed and corrected. Please also see Response to reviewer 2 comment.

(4) Please use full names of abbreviations before using abbreviations.
Response:
We agree with reviewer’s opinion and use full names of abbreviations before using abbreviations, such as “The levels of phosphorylated low-density lipoprotein receptor related protein 6 (LRP6)” in abstract method section, in which full name of LRP6 was used before LRP6.
Thank you so much for your consideration, and we are looking forward to publication soon.
Sincerely yours,

Desheng Lu, MD, Ph.D
Cancer Research Center
Department of Pharmacology
School of Medicine, Shenzhen University
Shenzhen 518060, China
Email: delu@szu.edu.cn